Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1193 | Dexamethasone Wiki | 0.33 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003704 | Dementia NIH | 0.35 |
| D003324 | Coronary Artery Disease NIH | 0.33 |
| D060825 | Cognitive Dysfunction NIH | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000726 | Dementia HPO | 0.35 |
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.33 |
| HP:0001268 | Mental deterioration HPO | 0.26 |
Navigate: Correlations HPO
There is one clinical trial.
The aim of this project is to study the safety and efficacy of anthocyanins in improving key dementia-related mechanisms and cognitive functioning in older people at risk for dementia. Secondary analyses will include a variety of biological measures, including biochemistry, imaging and cardiovascular measures.
Description: A composite measure from the CogTrack battery
Measure: Quality of episodic memory. Time: Baseline to 24 weeksDescription: CogTrack evaluates attentional intensity index, sustained intensity index, cognitive reaction time, attentional fluctuation index, quality of working memory, quality of episodic memory and speed of memory retrieval.
Measure: Secondary endpoints from CogTrack Time: Baseline to 24 weeksDescription: Lipid profile, fatty acids, cytokines ( among others: IL-1, IL-2, IL-6, TNF-a), plasma antoxidant status and vitamins (lipid peroxidation markers, vitamins E, C, A, total plasma antioxidant capacity, glutathion)., carinthine, blood glucose, HbA1c, anthocyanins and metabolites, mapping of a-beta degradation products.
Measure: Blood outcome analysis Time: Baseline to 24 weeksDescription: Flow-mediated dilation (FMD), Cardiac-ankle vascular index (CAVI), photoplethysmogram (PPG).
Measure: Cardiovascular parameters Time: Baseline to 24 weeksDescription: Microbiota
Measure: Fecal analysis Time: Baseline to 24 weeksDescription: kyrinin
Measure: Urine analysis Time: Baseline to 24 weeksDescription: anthocyanin metabolites
Measure: CSF measurements Time: Baseline to 24 weeksDescription: Diagnosing and follow-up of cerebrovascular disease
Measure: MR-imaging/CT Time: Baseline to 24 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports